Exploring Traditional and Novel Diagnostic Biomarkers for Liver Fibrosis: A Comprehensive Review

Abstract

Liver fibrosis is a widespread health issue brought on by a number of causes. A disease's early diagnosis is crucial for improved patient management. Different causes of persistent liver damage can result in hepatic fibrosis. One of the most important steps in determining the disease's severity is determining the degree of liver fibrosis. A disease's early diagnosis is crucial for improved patient management. There are various traditional biomarkers present for diagnosing various stages of liver fibrosis, but these traditional biomarkers have certain limitations. Liver fibrosis having low specificity (ability to determine the etiology) and low sensitivity. In medical practice, test for liver fibrosis have limited usefulness (distinguish intermediate stages). A liver biopsy is a gold standard for evaluating the stage of hepatic fibrosis, despite the fact that it has many disadvantages. Over the past ten years, several noninvasive new markers for identifying the stage of hepatic fibrosis have been created. Some are comparable to liver biopsy and have solid validation. This article aimed that Novel diagnostic biomarkers may prove to be very helpful in the near future for identifying the stages of liver fibrosis and may be just as significant as liver biopsies in doing so.